September 20, 2024 10:27 AM Eastern Daylight Time GLASGOW, Scotland–(BUSINESS WIRE)–Maja Schmidt, in collaboration with Neuranics Limited and the University of Edinburgh, has been awarded the highly coveted Royal Commission for the Exhibition of 1851 Industrial Fellowship for her innovative AI-driven remote heart health monitoring project. This initiative aims to […]
Financial
Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ — Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and…
CARMAT Launches a Capital Increase for an Initial Amount of €10.3 Million to Finance Its Activities Until at Least the End of 2024
This capital increase will be carried out through a public offering without preferential subscription rights and with a 7 trading days priority period, on an irreducible and reducible basis, for the benefit of CARMAT’s shareholders The initial amount of the capital increase may be increased up to €11.8 million in […]
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company has regained full compliance with the Nasdaq Capital Market’s Listing Requirements as required by the Hearing Panel’s (the “Panel”) decision on May 13, 2024.
Novostia Announces New CEO and Secures Additional CHF 5.6 million in Funding
September 17, 2024 07:47 AM Eastern Daylight Time LAUSANNE, Switzerland–(BUSINESS WIRE)–Novostia, a pioneering medical technology company, specializing in the development of a disruptive heart valve prosthesis, at clinical stage, today announces a leadership transition alongside the successful completion of a CHF 5.6 million fund raise to further accelerate the company’s […]
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid…
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update.
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced a $50M Series B funding round led by Johnson & Johnson Innovation – JJDC, Inc. joined by S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, […]
Merit Medical to Present at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress
SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal.
Rivus Pharmaceuticals Strengthens Executive Team and Board with Appointments of Tom O’Neil as Chief Financial Officer and Erin Lavelle as Director
– Company continuing to advance clinical development of HU6, a novel oral, once-daily Controlled Metabolic Accelerator, in Phase 2 trials to treat obesity-related heart failure and metabolic dysfunction-associated steatohepatitis (MASH) – CHARLOTTESVILLE, Va. and SAN FRANCISCO, Sept. 11,…



